Iovance Biotherapeutics, Inc.
IOVA
Rank in Stocks
#2789
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Share Price
$14.87
Last synced: 2026-10-20
Market Cap
$6.74B
Change (1 day)
4.64%
Change (1 year)
555.03%
Country
US
Trade Iovance Biotherapeutics, Inc. (IOVA)
Category
Healthcare
Revenue for Iovance Biotherapeutics, Inc. (IOVA)
Revenue in Jun 2026 TTM: $324.97M
According to Iovance Biotherapeutics, Inc. latest financial reports the company's current revenue (TTM) is $324.97M. In 2023 the company made a revenue of $1.19M an increase over the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Iovance Biotherapeutics, Inc. from 2008 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $324.97M | 98.07% |
| 2024 | $164.07M | 13,698.99% |
| 2023 | $1.19M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 3,784.77% |
US
|
|
| $2.23B | 585.60% |
US
|
|
| $15.74B | 4,744.87% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,752.88% |
NL
|
